Evidence map›Paper›PMID 32379763›Full record

ArticlePloS one2020

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.

Sini Li, Liubao Peng, Chongqing Tan, Xiaohui Zeng, Xiaomin Wan, Xia Luo, Lidan Yi, Jianhe Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sini LiThe Xiangya Nursing School, Central South University, Changsha, Hunan, China.ORCID 0000-0002-1347-4024
Liubao PengDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chongqing TanDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiaohui ZengThe Second Xiangya Hospital, PET-CT Center, Central South University, Changsha, Hunan, China.
Xiaomin WanThe Xiangya Nursing School, Central South University, Changsha, Hunan, China.
Xia LuoDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Lidan YiDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jianhe LiDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThat clinical trial (RAINBOW) showed that a 7.4 months overall survival benefit with the combination therapy with ramucirumab (RAM) and paclitaxel (PAC) as second-line therapy for patients with recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma, compared with placebo (PLA) plus paclitaxel. We performed an analysis to assess the cost-effectiveness of RAM from a Chinese perspective and recognized the range of drug costs.

methodsBy building a Markov model to estimate quality-adjusted life-years (QALYs), life-years (LYs) and lifetime costs. Transition probabilities, costs and utilities were estimated for the published literature, Chinese health care system and local price setting. We performed threshold analyses and probabilistic sensitivity analyses to evaluate the uncertainty of the model.

resultsCompared with PLA strategy, RAM strategy provided an incremental survival benefit of 1.22 LYs and 0.64 QALYs. The probabilistic sensitivity analysis showed that when RAM costs less than $151 or $753 per 4 weeks, the incremental cost-effectiveness ratio (ICER) approximated the willingness-to-pay threshold (WTP), suggesting that there was 50% likelihood that the ICER for RAM + PAC would be less than $44528.4 per QALY or $48121 per QALY, respectively.

conclusionsFor patients with advanced gastric or gastro-oesophageal junction adenocarcinoma who fail first-line chemotherapy, our results are conducive to the multilateral drug price guidance negotiations of RAM in China.

Indexed as

AdenocarcinomaAdultAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAsian PeopleChinaCost-Benefit AnalysisEsophageal NeoplasmsFemaleHumansMaleMarkov ChainsMiddle AgedModels, EconomicPaclitaxelProgression-Free SurvivalAntibodies, Monoclonal, HumanizedPaclitaxelRamucirumab

Identifiers

PMID32379763
PMCPMC7205241
OpenAlexW3023184521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.